Rapport Therapeutics Jefferies Global Healthcare Conference
Review the key takeaways and the transcript of this earnings call.
Transcript
Preview the first fifteen paragraphs, organized by speaker.
Okay, we're going to get started with our next session. I'm Andrew Tsai, senior biotech analyst at Jefferies, and thank you for joining me today. We have the Rapport team with me. To my left is Abe Ceesay, the CEO. To my direct right is Troy Ignelzi, CFO, and to his right is Jeff Sevigny, CMO. To start, I think Abe will be sharing some prepared remarks. I'll let you take it away.
Great. Can I just ask how I advance slides?
As- Oh, here we go.
There we go. The one that says next and back. Perfect. All right. Well, good afternoon, everyone, and I want to just start by thanking Andrew and the rest of the Jefferies team for this opportunity. My name is Abe Ceesay. I'm the CEO here at Rapport Therapeutics. As a reminder, I will be making forward-looking statements throughout the presentation. Rapport is a company that was started through a collaboration between Third Rock and J&J to build a precision neuroscience company. We believe that precision really can come to life based on the scientific foundation of our company, which are receptor-associated proteins. The best way to think about receptor-associated proteins is through our lead program, which is a TARPγ8 AMPA modulator. I'll spend much more time on the novelty of this program as well as the indications that we're pursuing.
We launched Rapport and really thought about RAP-219 from the outset as a pipeline and a product opportunity. In 2025, we achieved proof of concept results with RAP-219 in focal onset seizures with truly unprecedented efficacy. Most recently, in 2026, we also achieved proof of concept with RAP-219 in bipolar mania. We're a well-capitalized company based on our recent financing on the backs of the bipolar data with roughly $814 million. Here's a quick snapshot of our pipeline. First, just looking at RAP-219 and orienting you to that pipeline and a product vision. We're currently enrolling our phase III studies in focal onset seizures, referred to as FOCUS 1 and FOCUS 2. We're also looking to initiate our phase III program in primary generalized tonic-clonic seizures, which is the next largest form of adult epilepsy.
Finally, as I spoke to on the previous slide, moving our bipolar mania trial into phase III. To round all of this out, we are developing a long-acting injectable formulation for RAP-219. We believe that this would be transformational for all indications that we're currently pursuing with the asset. In addition to RAP-219, we have a fully integrated discovery effort that is leveraging receptor associated proteins. Our lead program there is a nicotinic program, α6β4, which we're looking to move into the clinic for phase I in 2027. As you think about this pipeline and a product opportunity, it is one that is significant. As you look across the three populations, focal onset seizures, primary generalized tonic-clonic seizures, as well as bipolar mania, really represent multi-billion dollar market opportunities, primarily in focal onset seizures as well as bipolar mania.
As you think about the long-acting injectable, that has the opportunity to expand the clinical utility across all indications, but also really increase the terminal value of RAP-219 with the IP around the long-acting formulation being able to extend beyond the traditional composition of matter loss of exclusivity. So, let's take a moment to just reflect on the novelty and the potential for RAP-219 given the receptor associated protein science. TARPγ8, which is the receptor associated protein associated with the AMPA receptor, is primarily expressed in four brain structures, and you can see that reflected on the right-hand side in the PET receptor occupancy images. What's important about this is that concentration of TARPγ8 associated with AMPA receptors really overlays very nicely with what we understand around the disease biology in both focal onset seizures as well as bipolar mania.
Specifically for focal onset seizures start in the mesial temporal lobe as well as propagate in the mesial temporal lobe, as well as the cerebral cortex. In bipolar mania, what we understand about that disease is that disease is characterized by increased glutamate levels, and those glutamate levels are contained in a network, which is the cortico-limbic network, again, which overlays with the expression of TARPγ8. So, I first want to just review the data that we have seen with RAP-219 in focal onset seizures. We took an innovative approach to our proof of concept study. This proof of concept study specifically enrolled patients that were refractory focal onset seizure patients. That's the same type of patients that are ultimately enrolled in a phase III study. The innovative aspect of this study was that these patients had an implantable neurostimulation device known as the RNS device.
In terms of our trial, the stimulation or the treatment was not really important. What was important is that this device allows for constant EEG recording and allowed us to leverage a novel biomarker to make the study much more efficient, but also to corroborate the changes that we saw in clinical seizures. So, in terms of the results of that study, as I mentioned, these results were truly unprecedented in terms of efficacy that we observed with RAP-219. On the left-hand side, what you see is the primary endpoint, which is that electrographic endpoint or long episodes. You should consider these electrographic seizures. As you can see, we saw roughly a 71% reduction in electrographic seizures.
On the right-hand side, you can see how that corroborates the effects that we saw in clinical seizures, with a 78% reduction in clinical seizures, which is really unprecedented as you think about effects of anti-seizure medications. Importantly, on the far-hand right bar, what you see is a 24% seizure freedom rate. This is ultimately what is the goal of care for patients. A 24% seizure freedom rate, one, is not impacted by placebo. Overall, seizure freedom is not impacted by placebo, but the 24% of patients achieving seizure freedom is really one of the highest that has been observed with anti-seizure medications. From a tolerability standpoint, the drug was well tolerated. You can see that the most common AEs were dizziness, headache, and fatigue. All AEs were mild to moderate. Now moving to our bipolar data.
Before I go through the actual results of the bipolar data, I want to set the context for the bipolar patient. This is a patient population that has significant unmet need. These patients show up either in the inpatient or outpatient setting in a manic episode. They are treated acutely today with three main areas of treatment. One is atypical antipsychotics, two are the anti-seizure medications that are approved for bipolar, and then third is lithium. All of these current medications for these patients carry very burdensome AE profile, and ultimately what occurs is that unfortunately these patients have a very high discontinuation rate. Roughly 40% of patients discontinue, and then we are back in a cycle for these patients where they are ultimately cycling back to another manic episode.
The AEs that are most common with currently available therapies are all of the AEs that are well-known for atypical antipsychotics, sedation, akathisia, extrapyramidal symptoms, weight gain, metabolic changes, as an example, and all of these AEs are AEs that ultimately drive patients to stop taking their treatment. We believe that RAP-219 could be transformational for this patient population. The first aspect is that there has not been a novel mechanism in bipolar mania in over three decades. Presenting a novel mechanism of action for this patient population could be very important. Second, given the profile of RAP-219, one, it is not interrogating the dopaminergic channel, and two, it is approaching a different neurotransmitter in glutamate, we believe could be a really nice option both for clinicians as well as patients. We just completed, as I mentioned, our phase II proof of concept trial.
This was a standard trial in bipolar mania, one that was not innovative, such as our proof of concept study in epilepsy, a very standard approach. It was a large placebo-controlled randomized trial. It consisted of three weeks, or 21 days, of inpatient treatment, followed by an eight-week follow-up period. Just a quick snapshot of the patient disposition. You can see that 253 patients were randomized, 127 in the placebo arm, 126 in the RAP-219 arm. You can see the discontinuation of treatment. There were 31 patients in the RAP-219 arm compared to 15 patients in the placebo arm. You can see the main reason for discontinuation across both arms was withdrawal of consent, which is a common reason why patients withdraw in bipolar mania studies. You can see that there is an imbalance between RAP-219 as well as placebo. Importantly, this discontinuation was not driven by AEs.
When we understand and look further at this data and understand why patients were withdrawing from consent, our understanding is that patients that were on RAP-219 were either at baseline or actually improving, as compared to placebo patients that were either at baseline or worsening. You can see the overall withdrawal rate due to AEs was low, with 3.2% in the RAP-219 arm compared to 0.8% in the placebo arm. Looking at the primary endpoint, which is the YMRS, which is the standard endpoint for bipolar mania, we observed a 3.1 placebo-adjusted difference in the YMRS scale at week three. Importantly, as you look at these results, what you can see is a clear, consistent effect of the treatment arm. The lines never touch or never cross going across the treatment period.
What you can also observe is the absolute change in the treatment arm, RAP-219, of 15.4. This is a very meaningful change. Looking historically based on drug development in bipolar mania, 15.4 is in the top 5 absolute effects that you see in all other trials, in all other agents. Importantly, when you look at the YMRS, the YMRS contains 11 single items that make up the overall scale. When we look at these 11 items, all 11 items improved on drug. Importantly, four items met significance, and those are irritability, content, disruptive aggressive behavior, and as well as sexual interest. The top 3, irritability, content, disruptive, and aggressive behavior are some of the most important measures of a manic episode, and ultimately are the items that either drive hospitalization or keep patients hospitalized.
FULL TRANSCRIPT
Continue the full translated transcript in StockNow.
Access every statement, the English original, and speaker-by-speaker history with StockNow Pro.
View the full transcript with ProCall participants
3 people spoke on this call — only 1 are shown here.
PARTICIPANT LIST
View participant details in StockNow.
Log in to see executives and analysts, their roles, and complete speaking history.
Log in to view all participantsKeep exploring
